Sleep Disorders Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults who are suspected of having obstructive sleep apnoea (a condition where breathing repeatedly stops during sleep) and who have been recommended to have a sleep study (polysomnography)
Who may not be able to join:
- People under 18 years of age
- People who are unable to read or understand the study consent information due to vision difficulties, intellectual challenges, or language barriers
- People who have a neuromuscular disease (a condition affecting the nerves and muscles) or a chest wall disease where reduced breathing during sleep is also suspected
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Bertien Buyse, MD, PhD, Universitaire Ziekenhuizen KU Leuven
Phone: +32 16 342522
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Variability in oxygen desaturation index 3 percent; Variability in oxygen desaturation index 4 percent; Variability in mean oxygen saturation; Variability in minimal oxygen saturation; Variability in percentage of time oxygen saturation < 90 percent; Variability in percentage of time oxygen saturation < 88 percent; Variability in percentage of time oxygen saturation < 80 percent
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.